Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer

Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188926. doi: 10.1016/j.bbcan.2023.188926. Epub 2023 May 23.

Abstract

Bladder cancer (BC) has high morbidity and mortality rates owing to challenges in clinical diagnosis and treatment. Advanced BC is prone to recurrence after surgery, necessitating early diagnosis and recurrence monitoring to improve the prognosis of patients. Traditional detection methods for BC include cystoscopy, cytology, and imaging; however, these methods have drawbacks such as invasiveness, lack of sensitivity, and high costs. Existing reviews on BC focus on treatment and management and lack a comprehensive assessment of biomarkers. Our article reviews various biomarkers for the early diagnosis and recurrence monitoring of BC and outlines the existing challenges associated with their application and possible solutions. Furthermore, this study highlights the potential application of urine biomarkers as a non-invasive, inexpensive adjunctive test for screening high-risk populations or evaluating patients with suspected BC symptoms, thereby alleviating the discomfort and financial burden associated with cystoscopy and improving patient survival.

Keywords: Biomarker; Bladder cancer; Early diagnosis; Recurrence monitoring.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor* / genetics
  • Cystoscopy / methods
  • Early Diagnosis
  • Humans
  • Risk Factors
  • Urinary Bladder Neoplasms* / diagnosis
  • Urinary Bladder Neoplasms* / surgery

Substances

  • Biomarkers, Tumor